Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients
Authors:
- 25 August 2021
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 39 (9) , 777-782
Abstract
Multiple myeloma is an incurable hematological malignancy. Currently, the use of proteasome inhibitors could be superior to chemotherapy-based regimen in the treatment of this disease. However, resistance to bortezomib combination therapy still occurs in some patients. So, this research work aims to assess CD69 and CD56 expression in these cases and their relation to the response to therapy. Immunophenotyping by 4-color multi-parameter flow cytometry was carried out on 98 multiple myeloma cases. Clonal plasma cells were gated by co-expression of CD38 with CD138 with low SSC, negative or dim CD45. Double negative CD69 and CD56 (47.9%) multiple myeloma cases were associated with high serum β2 microglobulin, creatinine, calcium and low serum albumin. There was also a significant correlation between the absence of these markers with osteolytic lesions and unfavorable cytogenetic t (4;14) (p < 0.001). Moreover, there was a highly significant correlation between CD69- and CD56- with non-response to bortezomib combination therapy in multiple myeloma patients (p < 0.0001). Regression analysis for the prediction of non- response to treatment in these cases using different prognostic indicators revealed that high serum β2 microglobulin, unfavorable cytogenetic, advanced stage, and low expression of CD69 and CD56 were poor predictors of non-response. CD69 in association with CD56 could be an independent prognostic factor in multiple myeloma cases. It could be used in the routine laboratory assessment for refining stratification and timely therapeutic decision for highly cost therapy in developing countries.Keywords
Funding Information
- Deanship of Scientific Research at King Khalid University, Abha,
This publication has 23 references indexed in Scilit:
- Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysisBioscience Reports, 2017
- CD69: from activation marker to metabolic gatekeeperEuropean Journal of Immunology, 2017
- Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomibOncology Letters, 2017
- The Evolution of Prognostic Factors in Multiple MyelomaAdvances in Hematology, 2017
- Human NK cell development requires CD56-mediated motility and formation of the developmental synapseNature Communications, 2016
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma ModelMolecular Cancer Therapeutics, 2013
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapyHaematologica, 2012
- CD69 Association with Jak3/Stat5 Proteins Regulates Th17 Cell DifferentiationMolecular and Cellular Biology, 2010
- Prognostic Significance of Surface Markers Expressed in Multiple Myeloma: CD56 and Other AntigensLeukemia & Lymphoma, 2004
- Cell‐cycle control of plasma cell differentiation and tumorigenesisImmunological Reviews, 2003